Format

Send to

Choose Destination
Leuk Lymphoma. 2017 Mar;58(3):560-568. doi: 10.1080/10428194.2016.1207763. Epub 2016 Jul 18.

Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide.

Author information

1
a Department of Cancer Epidemiology , Moffitt Cancer Center , Tampa , FL , USA.
2
b Department of Malignant Hematology , Moffitt Cancer Center , Tampa , FL , USA.
3
c Biostatistics Core, University of New Mexico Cancer Center , Albuquerque , NM , USA.
4
d Department of Biostatistics , Moffitt Cancer Center , Tampa , FL , USA.
5
e Celgene Corporation , Summit , NJ , USA.
6
f DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center/M2GEN , Tampa , FL , USA.

Abstract

Risk of subsequent primary malignancies (SPMs) associated with lenalidomide therapy in multiple myeloma (MM) patients, outside the context of melphalan-based therapy is not established. We assessed the risk of SPMs in lenalidomide treated MM patients (n = 1653) at Moffitt Cancer Center (2004-2012) outside the context of melphalan-based induction therapy and post-melphalan maintenance therapy, via (1) cohort analysis and (2) nested case-control study. Incident SPMs (n = 51) were matched to controls (n = 102) on age at MM diagnosis, gender, follow-up time, and date of diagnosis. Incidence of SPM differed significantly (p = 0.0038) between MM patients treated with and without lenalidomide (5-year incidence estimates of 3.2 and 6.2%, respectively), although not significant after adjustment for age and year of diagnosis (HR = 0.82, 95%CI = 0.43-1.57). Lenalidomide treatment was inversely associated with SPM in the nested case-control analysis (OR = 0.03, 95%CI = 0.002-0.34). In this large cohort of MM patients, lenalidomide treatment was not associated with an increased risk of SPM.

KEYWORDS:

Multiple myeloma; lenalidomide; subsequent malignancy

PMID:
27424609
DOI:
10.1080/10428194.2016.1207763
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center